CD11b and CD200 on Circulating Monocytes Differentiate Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy

Yousif Subhi,1,2 Marie Krogh Nielsen,1,2 Christopher Rue Molbech,1,2 Akio Oishi,3 Amardeep Singh,1,4 Mogens Holst Nissen,2,5 and Torben Lykke Sørensen1,2

1Clinical Eye Research Division, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark
2Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark
3Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
4Department of Clinical Sciences Lund, Ophthalmology, Skane University Hospital, Lund University, Lund, Sweden
5Eye Research Unit, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark


PURPOSE. To investigate surface expression of CD11b and CD200 on circulating monocytes in patients with polypoidal choroidal vasculopathy (PCV).

METHODS. This was a prospective case-control study of patients with PCV (n = 27), age-matched healthy controls (n = 27), and patients with neovascular AMD (n = 49). All participants underwent a comprehensive ocular examination. Fluorescein and indocyanine green angiography were performed in patients suspected of neovascular AMD or PCV. Polypoidal choroidal vasculopathy was angiographically categorized into those with a strong presence of a branching vascular network (BVN) (type 1) or with a faint/no clear presence of a BVN (type 2). Fresh venous blood was stained with fluorescent antibodies for flow cytometric analyses. We compared the percentages of CD11b+ and CD200+ and CD11b+CD200+ monocytes between groups of diagnosis and between different angiographic subtypes of PCV.

RESULTS. Overall, CD11b+ monocytes were both increased in patients with PCV and neovascular AMD. CD200+ and CD11b+CD200+ monocytes were increased in patients with neovascular AMD. An age-related increase in CD11b+CD200+ monocytes was absent in patients with PCV and neovascular AMD. Patients with PCV type 1 had significantly higher CD11b+, CD200+, and CD11b+CD200+ monocytes, whereas patients with PCV type 2 had levels similar to that in healthy controls.

CONCLUSIONS. We found that PCV is immunologically heterogeneous with significant differences between angiographic subtypes. Increased CD11b+ and CD200+ monocytes in those with a strong presence of BVN indicate that BVN development may be associated with retinal injury and a VEGF-mediated process that is either reflected or propelled by systemic changes in monocytes.

Keywords: polypoidal choroidal vasculopathy, immunology, microglia, blood, monocytes

Age-related macular degeneration is the most common cause of irreversible vision loss in the elderly of the developed world.1 The late stage of the disease includes an exudative phenotype where proliferating choroidal vessels break through the Bruch’s membrane resulting in hemorrhage and exudate in the macula, which impairs visual acuity and function.2–4 Although the etiology of neovascular AMD is not fully understood, growing evidence suggest a key role for chronic neuroinflammation and microglial activity (resident macrophages of the retina) that result in a proinflammatory environment wherein VEGF secretion is a drive-force for the choroidal neovascularizations (CNV).5–7 An important differential diagnosis to neovascular AMD is polypoidal choroidal vasculopathy (PCV). Polypoidal choroidal vasculopathy was initially described by Yannuzzi8 in 1982 as a variant of CNV in the peripapillary area, and since as a clinical entity distinctly different from neovascular AMD in choroidal originated polyplike structures with or without associated branching vascular network (BVN) typically under the RPE.9–12 Although the clinical phenotype of PCV is clearly distinct from that of neovascular AMD, it is still debated whether they share similar etiology or also differ etiologically.12,13 Tong et al.14 found that intraocular levels of VEGF may be increased in PCV, but at a lower level than in neovascular AMD. Genetic studies suggest similarities and differences in the etiology of PCV and neovascular AMD.15–17 A recent example is a missense variant in the FGD6 (FYVE, RhoGEF, and PF domain-containing protein 6) gene that contributes to angiogenesis only in PCV and not in neovascular AMD.17 However, the amount of studies focusing on PCV is limited and etiologic aspects as well as similarities and differences between neovascular AMD and PCV remain to be understood.

Intravitreal VEGF inhibitors is a part of the treatment of PCV and VEGF is suspected to play an important role in the
etiology. Interestingly, recent reports of treatment outcomes suggest that PCVs with a strong presence of BVN respond better to anti-VEGF treatment than PCVs without or very faint BVNs. These results suggest that there may be differences in the etiologic mechanisms between these angiographic subtypes. Indeed, genetic studies have found differences in the genetic background when comparing patients with these different angiographic subtypes, and patients with PCV with a strong presence of BVN are more likely to have a genetic composition similar to that seen in patients with neovascular AMD. Polyps without or very faint BVN on the other hand have been associated with single nucleotide polymorphisms in the elastin gene suggesting a genetic predisposition to uncontrolled microglia activity and CD200 overexpression is likely to have a genetic composition similar to that seen in patients with neovascular AMD.

There is a growing interest in the role of circulating monocytes in AMD. Macrophages (i.e., monocytes at site of injury that are differentiated into active phagocytes) possess both the capability of facilitating clearance of drusen and fostering an environment that eventually leads to CNV. Their multifaceted function gives rise to conflicting hypotheses wherein they are the culprits, the saviors, or both. Surface expression of CD11b and CD200 on monocytes have previously been associated with neovascular AMD. CD11b regulates the monocyte adhesion and migration processes in response to inflammation and CD11b+ monocytes secrete VEGF at sites of inflammation significantly contributing to the formation of CNVs. Activity of retinal microglia is regulated through CD200 receptor (CD200R) interaction with monocytes CD200 inhibition leads to uncontrolled microglia activity and CD200 overexpression is a regulatory mechanism, whereby neurons and resident or infiltrating immune cells attenuate microglial activity.

These etiologic aspects of circulating monocytes remain completely unexplored for PCV. Hence, in this study, we investigated the surface expression of CD11b and CD200 on circulating monocytes in patients with PCV and compared with healthy controls and patients with neovascular AMD.

**Methods**

This was a prospective case-control study of patients with PCV, patients with neovascular AMD, and healthy control individuals. We explained the nature of the study to all participants and obtained oral and written consent prior to participation. This study was approved by the Regional Committee of Ethics in Research of the Region of Zealand (SJ-379) and followed the principles stated in the Declaration of Helsinki.

**Study Participants**

We recruited visitors to the Department of Ophthalmology at Zealand University Hospital Roskilde between February 2015 and February 2017 for this prospective case-control study. Patients with neovascular AMD or PCV were recruited consecutively from our outpatient program. Age-matched control individuals above 60 years of age were recruited among healthy visitors, who were primarily a biologically unrelated relative (e.g., husband or wife) to a recruited patient with neovascular AMD or PCV. This was an intentional strategy to match the control group in terms of lifestyles and exposures. Because no previous studies have investigated CD11b and CD200 in patients with PCV, power calculations were based on previous immunologic studies on patients with neovascular AMD. Assuming an alpha level of 0.05, and a power level of 80%, we calculated that a sample size of 26 in each group was necessary to obtain sufficient power to detect differences in CD11b/CD200 between the three groups of diagnosis.

**Retinal Diagnosis, Clinical Data, and Interviews**

Patients were examined using slit-lamp biomicroscopy, digital fundus photography, and spectral-domain optical coherence tomography (SD-OCT). Best-corrected visual acuity (BCVA) was measured in each eye using the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Healthy controls were defined as having less than 10 small drusen (diameter <63 μm) without pigment abnormalities. Fluorescein and indocyanine green angiography (ICGA) was used for subtyping the disease to neovascular AMD or PCV. Neovascular AMD included cases with fibrovascular pigment epithelium detachments and CNV membranes with subretinal or sub-RPE hemorrhages or fibrosis. Polypoidal choroidal vasculopathy was diagnosed in cases with one or more polyps seen in the early-phase ICGA with a hypofluorescent halo and with or without BVN. The ICGA video was used to evaluate the pulsation of polyps. Other PCV characteristics were not mandatory for the diagnosis, but were used to support the final diagnosis (funds examination revealing orange-red focal subretinal polyp-like structures and retinal OCT showing a protrusion from the choroid elevating RPE from the Bruch’s membrane). We further categorized PCs into subtypes based on ICGA presence of BVN: type 1, polypoidal lesions with visible feeder and draining vessels and strong presence of BVNs; or type 2, polypoidal lesions without clear visible feeder or draining vessels and without or faint BVNs.

All participants were interviewed to obtain a list of medical conditions, and ongoing treatments and medications. Data were crosschecked with the patient’s electronic patient record. Smoking habits was categorized in current smokers, previous smokers (smoked >100 cigarettes during lifetime and ceased smoking >12 months), or never smokers. Alcohol use was reported in units/week (1 unit = 12-mL ethanol). Physical activity was assessed using a single question on regular activity. Height and weight was measured to calculate body mass index.

**Participant Eligibility**

Eligible participants had either healthy retinas, neovascular AMD in one or both eyes, or PCV in one or both eyes. Because we measured the systemic immune phenotype of the individuals, we restricted our study population to individuals without ongoing immune diseases that can affect our results and blur our conclusions. Thus, we did not include participants with a diagnosis of cancer, autoimmune disease, or any immune, infectious, or inflammatory diseases, or patients who were receiving chemotherapy or any immune modulating therapy. We also did not include participants that had received VEGF inhibitors (anti-VEGF) within the last 4 or 8 weeks for ranibizumab and aflibercept, respectively, to avoid potential interaction of systemic antibodies in the following preparations. Retinal diagnosis including retinal angiography was made on treatment-naive eyes, but patients were not recruited on their first visit as onset of CNV is associated with acute immune activity. Eligible patients were identified and recruited from follow-up visits. We post-hoc excluded participants with elevated plasma C-reactive protein levels as this is a sign of ongoing immune disease.

**Blood Sampling, Preparation, and Flow Cytometry**

Venous blood from antecubital veins were sampled in an EDTA-coated tube for flow cytometric analyses and a lithium heparin
coated tube for serum CRP measurement. Flow cytometry was performed within 4 hours after blood sampling. We used an automated hematology analyzer Sysmex KX-21N (Sysmex Corporation, Kobe, Japan) to obtain the white blood cell count, which was used to calculate the volume of blood needed to obtain $5 \times 10^8$ white blood cells in each test tube. The red blood cells were lysed using 1% red blood cell lysis buffer (Nordic Biosite AB, Täby, Sweden) for 10 minutes at room temperature and in the dark. Cells were washed in an isotonic buffer (BD FACSCflow; BD Biosciences, Franklin Lakes, NJ, USA) and centrifuged for 5 minutes at 500g. This process was repeated three times, after which the cells were resuspended in the isotonic buffer. We then added the following monoclonal antibodies: Allophycocyanin-CD71b, IgG1 κ, Clone ICRF44, Cat. No. 557754 (BD Biosciences); Phycoerythrin-CD71b CD144, IgG2a κ, Clone M5E2, Cat. No. 301814 (BioLegend, San Diego, CA, USA); and Phycoerythrin CD200, IgG1 κ, Clone 325516, Cat. No. FAB27241P (R&D Systems, Inc., Minneapolis, MN, USA). Fluorochrome-matched negative isotypes were added to a separately prepared tube: Allophycocyanin-CD71b IgG1 κ, Clone MOPC-21, Cat. No. 400128 (BioLegend); Phycoerythrin-CD71b IgG2a κ, Clone MOPC-173, Cat. No. 400232 (BioLegend); and Phycoerythrin IgG1 κ, Clone MOPC-21, Cat. No. 555749 (BD Biosciences). Incubation was done at room temperature in the dark for 20 minutes, after which the cells were washed and resuspended in the isotonic FACSCflow buffer. Stained cells were analyzed using flow cytometry (BD FACSCanto II; BD Biosciences) with a sample size gated for 100,000 singlet leukocytes. Flow data were analyzed using Kaluza Analysis (Kaluza Analysis v. 1.5.20565.161; Beckman Coulter, Inc., Pasadena, CA, USA) by two independent evaluators (YS and MKN) who were blinded to the conditions of the participants. We used cell height and area to gate singlets and size and granularity forward scatter (FSC)/side scatter (SSC) to gate monocytes, which was then used to investigate expression of the markers investigated (Fig. 1). Nonspecific signaling was eliminated using corresponding negative isotype controls with a threshold of 1%.

**Data Analysis and Statistics**

All statistics were performed using SPSS 23 (IBM Corporation, Armonk, NY, USA) and presented using Prism 7 (GraphPad, La Jolla, CA, USA). Normally distributed continuous data were presented in mean and SD and compared using parametric tests; otherwise data were presented in median and interquartile range (IQR) and compared using nonparametric tests. Categoric variables were presented in numbers and percent and tested using χ² test, and we used the Fisher’s exact test when dealing with small categories. We compared the frequencies of monocytes that were CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ between the groups. To evaluate the size of the observed differences between the groups, we calculated Cohen’s d, which is defined as the ratio between the group difference and the SD for the data and interpreted following the suggestions by Cohen and Sawilowsky: $<0.2$ (negligible/very small), $0.2$ (small), $0.5$ (moderate), $0.8$ (large), and $1.2$ (very large).36,39 We explored immunosenescence (i.e., age-dependent changes of the immune system) for CD11b⁺CD200⁺ monocytes, for which we previously found an age-related increment in healthy individuals that was absent in patients with neovascular AMD.37,38 Finally, we explored differences in CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ monocytes among patients with PCV stratified by their angiographic subtype. P values below 0.05 were interpreted as sign of statistical significance.

**RESULTS**

We recruited 31 healthy controls, 27 patients with PCV, and 54 patients with neovascular AMD for this study during the enrollment period. All participants were Caucasians. Due to high plasma C-reactive protein levels (>15 mg/L), indicating a possible ongoing acute immune response, four healthy controls and five patients with neovascular AMD were excluded. Thus, our analyses include a total of 103 participants consisting of 27 healthy controls, 27 patients with PCV, and 49 patients with neovascular AMD. Time from initial retinal diagnosis for patients with PCV or neovascular AMD to study recruitment and blood sampling were median 16 (IQR: 4–36) months and median 18 (9–38) months, respectively, for patients with PCV and patients with neovascular AMD. Groups did not differ in in demographics, co-morbidities, or lifestyle factors (Table 1), but differed significantly in CD11b⁺ monocytes ($P < 0.001$, one-way ANOVA), CD200⁺ monocytes ($P = 0.009$, one-way ANOVA), and CD11b⁺CD200⁺ monocytes ($P = 0.014$, one-way ANOVA).

Patients with PCV had significantly higher CD11b⁺ monocytes than healthy controls, but CD200⁺ monocytes did not differ (Fig. 2). Percentage of CD11b⁺ monocytes was significantly higher than in healthy controls (mean difference: 2.9%, confidence interval [CI] 95%: 0.8%–5.0%, $P = 0.008$, independent samples t-test). Percentage of CD200⁺ monocytes did not differ significantly from healthy controls (mean difference: 0.8%, CI 95%: −4.0% to 5.7%, $P = 0.740$, independent samples t-test). Percentage of CD11b⁺CD200⁺ monocytes also did not differ significantly from healthy controls (mean difference: 0.3%, CI 95%: −4.2% to 5.9%, $P = 0.735$, independent samples t-test). Time from retinal diagnosis to blood sampling (duration of disease) did not correlate with percentages of CD11b⁺ monocytes ($r = 0.10$, $P = 0.604$, Spearman’s correlation), CD200⁺ monocytes ($r = 0.04$, $P = 0.838$, Spearman’s correlation), or CD11b⁺CD200⁺ monocytes ($r = 0.05$, $P = 0.796$, Spearman’s correlation).

Patients with neovascular AMD had significantly higher CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ monocytes compared with healthy controls (Fig. 2). Percentage of CD11b⁺ monocytes was significantly higher than in healthy controls (mean difference: 5.2%, CI 95%: 3.1%–7.2%, $P < 0.001$, independent samples t-test). Percentage of CD200⁺ monocytes was significantly higher than in healthy controls (mean difference: 0.3%, CI 95%: 0.0%–1.6%, $P = 0.048$, independent samples t-test). Percentage of CD11b⁺CD200⁺ monocytes was also significantly higher than in healthy controls (mean difference: 6.4%, CI 95%: 2.0%–10.7%, $P = 0.009$, independent samples t-test). Time from retinal diagnosis to blood sampling (duration of disease) did not correlate with percentages of CD11b⁺ monocytes ($r = 0.10$, $P = 0.478$, Spearman’s correlation), CD200⁺ monocytes ($r = 0.08$, $P = 0.601$, Spearman’s correlation), or CD11b⁺CD200⁺ monocytes ($r = 0.08$, $P = 0.578$, Spearman’s correlation).

Patients with PCV differed significantly from patients with neovascular AMD in CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ (Fig. 2). Patients with neovascular AMD had a significantly higher percentage of CD11b⁺ monocytes (mean difference: 2.3%, CI 95%: 0.9%–3.6%, $P = 0.001$, independent samples t-test), CD200⁺ monocytes (mean difference: 5.5%, CI 95%: 3.0%–10.7%, $P = 0.037$, independent samples t-test), and CD11b⁺CD200⁺ monocytes (mean difference: 5.5%, CI 95%: 1.0%–11.0%, $P = 0.048$, independent samples t-test).

Effect sizes of the group differences are shown in Table 2. The difference in CD11b⁺ monocytes between patients with PCV and healthy controls had a moderate size (Cohen’s d: 0.7). The difference in CD11b⁺ monocytes between patients with neovascular AMD and healthy controls had a very large size.
FIGURE 1. Gating strategies to identify CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ monocytes using flow cytometric data in Kaluza software. First, we identified singlets (A) and then monocytes using forward versus side scatter (B). Then, CD11b⁺ monocytes were identified (C). The CD200⁺ monocytes were less bright, and the percentage of CD200⁺ monocytes were determined using antibody corresponding negative isotype controls at 1% to distinguish positive cell populations from nonspecific background signals (D). The CD11b⁺CD200⁺ co-expressing monocytes was measured by identifying CD200⁺ monocytes among CD11b⁺ monocytes (E). We looked at CD14⁺ expression on the monocyte population to confirm that the population investigated was indeed monocytes (F).
(Cohen’s $d$: 1.3), whereas for the CD200$^+$ and CD11b$^+$CD200$^+$ monocytes the sizes were moderate (Cohen’s $d$: 0.6 and 0.6, respectively). The differences in CD11b$^+$, CD200$^+$, and CD11b$^+$CD200$^+$ monocytes between patients with PCV and patients with neovascular AMD were of moderate size (Cohen’s $d$: 0.6, 0.5, and 0.5, respectively).

In healthy controls, we found a positive correlation between age and CD11b$^+$CD200$^+$ monocytes ($\rho = 0.41$, $P = 0.035$, Spearman’s correlation) (Fig. 3). This age-related upregulation of CD11b$^+$CD200$^+$ was absent in patients with PCV ($\rho = -0.04$, $P = 0.854$, Spearman’s correlation) and in patients with neovascular AMD ($\rho = 0.03$, $P = 0.852$, Spearman’s correlation) (Fig. 3), which indicated that CD11b$^+$CD200$^+$ monocytes in patients with PCV may not be completely similar to that seen in healthy controls as indicated by comparisons between groups of diagnosis.

Patients with PCV type 1 ($n = 15$) differed significantly from those with type 2 ($n = 12$): CD11b$^+$ monocytes were significantly higher (mean difference: 2.85%, CI 95%: 0.9%-4.8%, $P = 0.008$, independent samples $t$-test), CD200$^+$ monocytes were significantly higher (mean difference 11.1%, CI 95%: 4.5%-17.6%, $P = 0.002$, independent samples $t$-test), and CD11b$^+$CD200$^+$ monocytes were significantly higher (mean difference 11.3%, CI 95%: 4.5%-18.0%, $P = 0.002$, independent samples $t$-test). Interestingly, CD11b$^+$, CD200$^+$, and CD11b$^+$CD200$^+$ measurements in patients with PCV type 1 were similar to those in patients with neovascular AMD, whereas measurements in patients with PCV type 2 were similar to those in healthy controls (Fig. 4). Patients with PCV type 1 did not differ from those with type 2 in terms of demographics, co-morbidities, or lifestyle factors ($P > 0.05$ for all comparisons).

**DISCUSSION**

Angiogenesis and CNV formation depend on monocyte dynamics.\textsuperscript{27,28} In this study, we find evidence of altered phenotype of circulating monocytes in patients with PCV.

### Table 1. Participant Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Patients With PCV ($n = 27$)</th>
<th>Healthy Controls ($n = 27$)</th>
<th>Patients With nAMD ($n = 49$)</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y mean (SD)</td>
<td>72.3 (7.6)</td>
<td>74.3 (7.5)</td>
<td>75.7 (7.4)</td>
<td>0.156</td>
</tr>
<tr>
<td>Sex, $n$, females:males</td>
<td>16:11</td>
<td>17:10</td>
<td>24:25</td>
<td>0.448</td>
</tr>
<tr>
<td><strong>Co-morbidities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension, $n$ (%)</td>
<td>11 (41)</td>
<td>10 (37)</td>
<td>25 (51)</td>
<td>0.448</td>
</tr>
<tr>
<td>Cardiovascular disease, $n$ (%)</td>
<td>5 (19)</td>
<td>3 (11)</td>
<td>11 (22)</td>
<td>0.494</td>
</tr>
<tr>
<td>Hypercholesterolemia, $n$ (%)</td>
<td>9 (33)</td>
<td>9 (33)</td>
<td>12 (25)</td>
<td>0.615</td>
</tr>
<tr>
<td>Type 2 diabetes, $n$ (%)</td>
<td>3 (11)</td>
<td>0 (0)</td>
<td>6 (12)</td>
<td>0.201</td>
</tr>
<tr>
<td><strong>Lifestyle factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking, $n$ (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.288</td>
</tr>
<tr>
<td>Current</td>
<td>8 (30)</td>
<td>4 (15)</td>
<td>15 (31)</td>
<td></td>
</tr>
<tr>
<td>Previous</td>
<td>15 (55)</td>
<td>13 (48)</td>
<td>21 (45)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>4 (15)</td>
<td>10 (37)</td>
<td>13 (26)</td>
<td></td>
</tr>
<tr>
<td>Alcohol consumption, units, median (IQR)</td>
<td>4 (1-13)</td>
<td>4 (2-7)</td>
<td>3 (1-9)</td>
<td>0.703</td>
</tr>
<tr>
<td>Body mass index, mean (SD)</td>
<td>25.4 (4.2)</td>
<td>25.5 (3.4)</td>
<td>26.3 (3.9)</td>
<td>0.537</td>
</tr>
<tr>
<td>Physically active, $n$ (%)</td>
<td>15 (56)</td>
<td>17 (63)</td>
<td>25 (51)</td>
<td>0.605</td>
</tr>
</tbody>
</table>
Table 2. Size of Differences (Cohen’s d) Between the Groups

<table>
<thead>
<tr>
<th></th>
<th>CD11b⁺ Monocytes</th>
<th>CD200⁺ Monocytes</th>
<th>CD11b⁺CD200⁻ Monocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with PCV vs. healthy controls</td>
<td>0.7 (moderate)</td>
<td>0.1 (very small)</td>
<td>0.1 (very small)</td>
</tr>
<tr>
<td>Patients with PCV vs. Patients with nAMD</td>
<td>0.6 (moderate)</td>
<td>0.5 (moderate)</td>
<td>0.5 (moderate)</td>
</tr>
<tr>
<td>Patients with nAMD vs. healthy controls</td>
<td>1.3 (very large)</td>
<td>0.6 (moderate)</td>
<td>0.6 (moderate)</td>
</tr>
</tbody>
</table>

Cohen’s d is calculated as the ratio between the difference between the groups and the SD for the data. Its interpretation is suggested by Cohen and Sawilowsky to the following: <0.2 (negligible/very small), 0.2 (small), 0.5 (moderate), 0.8 (large), and 1.2 (very large).

depending on angiographic subtype. Strong presence of BVN was associated with a higher percentage of CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ monocytes, at a level similar to that seen in patients with neovascular AMD, which suggests that VEGF and microglial activity play a role in BVN development. In contrast, no such changes were found in patients with PCV without or a very faint BVN, which from an immunologic perspective were similar to our healthy controls. These findings suggest that PCV constitute a heterogeneous disease entity, clinically as well as immunologically, wherein some aspects are similar to neovascular AMD while others differ.

Crosstalk between systemic circulating immune cells and the microglia is important for maintaining neuronal health.45,46 In the aged, anatomic, and physiological changes of the retina lead to an environment characterized by an increased need for phagocytosis of cellular by-products and lipoproteins in the outer retina.41,42 Increased neuronal stress and injury in the outer retina forces retinal microglia to migrate from inner to outer retina.43,44 As the resident phagocytes of the retina, the microglia increases their activity but may fail to keep up with the increasing phagocytic demand and retinal stress with age.43,44 This leads to an environment where circulating monocytes are increasingly recruited and macrophages accumulate in the retina to keep up with the need for phagocytosis and increased retinal stress.20,45 However, this balance in the retina wherein the monocytes comes in as the saviors is overthrown in the event of CNV formation in the late stage of AMD. Experimental models of laser-induced CNV demonstrate that monocytes infiltrate and determine the aftermath of the injury.27,28 Interestingly, experimental depletion of monocytes attenuates the size of CNV lesions,27,28 and similar positive correlation between monocytes and lesion size are seen in patients with recent onset of neovascular AMD.56 Contributing to a view of monocytes as the culprits of the story, specific monocyte phenotypes in the systemic circulation have been associated with neovascular AMD.46,47 Elucidating characteristics of these monocyte phenotypes is important to understand how immunologic ageing and dysfunction contributes to the etiology of AMD.

Ageing leads to an increased systemic expression of IL-10, which through Signal transducer and activator of transcription (STAT3)-mediated pathway polarizes macrophages into the proangiogenic M2 or CD14⁺CD16⁻ intermediate phenotypes.46-48 Blocking IL-10R or STAT3 leads to attenuated CNV in experimental models confirming the significance of these age-related monocyte/macrophage changes to the development of CNVs.46-47 These proangiogenic CD14⁺CD16⁻ monocytes have a higher expression of CD11b and adhere up to seven times more efficiently to vascular cell adhesion molecule 1,49,50 which is upregulated locally in eyes with neovascular AMD.51 These CD11b⁺ macrophages are a significant source of VEGF.51 Interestingly, presence of complement component 3 regulates CD11b expression and increased level of complement component 3 fragment C3a is found in patients with neovascular AMD.52,53 Taken together, these studies suggest that neovascular AMD is linked to a combination of immunologic ageing and dysfunction, and accordingly it is not surprising that our patients with neovascular AMD have a substantial increase in systemic levels of CD11b⁺ monocytes compared with age-matched healthy controls. In patients with PCV, CD11b⁺ monocytes were only moderately increased: however, delving into clinical details revealed that the level of CD11b⁺ monocytes did not differ significantly from the high levels seen in patients with neovascular AMD when focusing on patients with PCV type 1, whereas the level of CD11b⁺ monocytes in patients with PCV type 2 was comparable to healthy controls. Considering

![Figure 3](https://via.placeholder.com/150)

**Figure 3.** Scatterplots to explore relationship between CD11b⁺CD200⁺ (y-axis) and increasing age (x-axis) in healthy controls (A), patients with PCV (B), and patients with neovascular AMD (C) using Spearman’s correlation. In patients with PCV and in patients with neovascular AMD, no significant relationships were observed. In healthy controls (B), there was a positive correlation between age and CD11b⁺CD200⁺ monocytes.
that CD11b⁺ macrophages are a strong source of VEGF and that
BVNs consists of newly formed choroidal vessels, results of this
study suggest that VEGF may play a more substantial role for
the disease development in PCV type 1.

Signaling between neurons and monocytes/macrophages
through CD200:CD200R interaction can modulate microglial
and macrophage activity.30-32 Experimental autoimmune
retinitis leads to increased CD200R expression on microglia
and increased CD200 expression on neurons and infiltrating
cells, which suggests that CD200:CD200R interaction
is important in orchestrating a regulated microglial and
macrophage response.31 It is shown in CD200 knockout mice that
microglia becomes highly present and active in the retina,34
which confirms the regulatory role of CD200:CD200R interac-
tion on the microglia. In this current study, we find that
CD200⁺ monocytes and CD200⁺ on CD11b⁺ monocytes are
increased in patients with neovascular AMD, which is in line
with a previous study.24 Considering the regulatory function of
CD200, upregulation of systemic CD200 in patients with
neovascular AMD may be a regulatory mechanism to dampen
an increased microglial activity due to retinal stress, inflamma-
tion, and CNV. Our study adds to this knowledge as patients
with PCV were found to differ in their CD200⁺ monocytes
when stratified by angiographic subtype, suggesting strong
presence of BVN may be associated with an increased
microglial activity.

We previously found that ageing was correlated with
CD200⁺ on CD11b⁺ monocytes in healthy individuals,24
possibly due to increased microglial activity with age that is
counteracted by systemic regulation. This correlation was
missing in patients with neovascular AMD likely due to
generally upregulated CD200⁺ on monocytes. In this study,
we also found a correlation between age and CD111⁺CD200⁺
monocytes in healthy controls. Such correlations were lacking
in patients with PCV as well as in patients with neovascular
AMD, possibly reflecting an upregulation due to an increased
microglial activity.

Vascular dysfunction may play a significant role in PCV.
Jones et al.35 investigated previous associations between
HTRA1 and PCV by transgenically expressing human HTRA1
in mice RPE by which the mice developed choroidal-originated
BV and polypoidal lesions. Zeng et al.36 found that matrix
metalloproteinases 2 and 9, which regulate turnover of
extracellular tissue, were increased in the serum of patients
with PCV compared with early AMD, neovascular AMD, and
healthy controls. These studies indicate that there is a
significant component of vascular dysfunction in PCV. Histo-
pathologic examinations by Nakashizuka et al.57 identified
hyalinization of the choroidal vessels with foamy macrophages
similar to that seen atherosclerosis. Interestingly, binding of
LDL to CD11b⁺CD16⁺ intermediate proangiogenic circulating
monocytes is a key component in the differentiation toward
foamy macrophages.58

Taken together, we propose that our results and conclu-
sions from previous studies suggest an overall picture of PCV
type 1 as a vascular originated disease propelled by systemic
changes, which manifests as vascular pathologies primarily at
sub-RPE level; whereas neovascular AMD can be considered as
an intraretinal originated disease propelled by systemic
changes, which manifests as vascular and retinal pathologies
at intra- and subretinal level. In contrast, PCV type 2 may be a
vascular originated disease with a limited amount of retinal
damage. Future studies need to conform and elaborate on these
hypotheses.

It should be noted that our observational study design,
wherein we find associations and correlations does not
necessarily imply causation, which requires experimental
verification. We remain to elucidate whether the observed
changes in the circulatory system reflect a systemic adaptation
to retinal injury and microglial dysfunction, or whether the
changes reflect a fundamental disease in the immune system
that in the event of retinal stress causes vascular growth.
Another limitation is that our study uses a Caucasian
population and its generalizability to non-Caucasian popula-
tions may be complicated by PCV being subject to consider-
able interethnical differences as demonstrated in its
epidemiology, clinical characteristics, and genetic associa-
tions.12,13,59,60

In conclusion, we find that PCV from an immunologic
perspective constitute a heterogeneous disease entity with
important systemic differences between those with and
without BVN. Changes in CD11b and CD200 on monocytes
may reflect that BVN in PCV is a VEGF-mediated process that
is associated with an increased microglial activity or response,
whereas polyps without or very faint BVNs may differ
substantially in their underlying etiology. These findings shed
light on the mechanisms of a poorly understood disease and
suggest that there may not be a simple answer to the question
of whether or not PCV differs etiologically from AMD.

**Figure 4.** CD11b⁺, CD200⁺, and CD11b⁺CD200⁺ monocytes in patients with PCV stratified by angiographic subtype at time of diagnosis. Whiskers represent mean and ± standard error. Corresponding mean of healthy controls (dashed line) and mean of patients with nAMD (dotted line) are included for reference. Polypoidal choroidal vasculopathy type 1 was associated with higher CD11b⁺ (A), CD200⁺ (B), and CD11b⁺CD200⁺ (C) monocytes when compared with PCV type 2.
Acknowledgments

Supported by grants from the Danish Eye Research Foundation (Taastrup, Denmark), Fight for Sight Denmark (Copenhagen, Denmark), and the Velux Foundation (Soborg, Denmark).

Disclosure: Y. Subhi, Novartis (R), Bayer (R); M. Krogsh Nielsen, Novartis (R); C.R. Molbech, Bayer (R); A. Oishi, Novartis (F, R), Alcon (F), Bayer (R); A. Singh, Novartis (R), Bayer (R); M.H. Nissen, None; T.L. Sørensen, None

References


34. Subhi Y, Singh A, Falk MK, Sørensen TL. In patients with neovascular age-related macular degeneration, physical activ-


